These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19179633)

  • 21. New and generic anticoagulants and biosimilars: safety considerations.
    Kalodiki E; Fareed J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis and characterization of heparin impurities.
    Beni S; Limtiaco JF; Larive CK
    Anal Bioanal Chem; 2011 Jan; 399(2):527-39. PubMed ID: 20814668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
    McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
    J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contaminated heparin.
    Kakkar AK; Bonnefoi M
    N Engl J Med; 2008 Sep; 359(12):1292-3; author reply 1293. PubMed ID: 18810795
    [No Abstract]   [Full Text] [Related]  

  • 25. Electrophoresis for the analysis of heparin purity and quality.
    Volpi N; Maccari F; Suwan J; Linhardt RJ
    Electrophoresis; 2012 Jun; 33(11):1531-7. PubMed ID: 22736353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins.
    Martin M; Ott H; Merk HF; Sachs B
    Br J Dermatol; 2011 Jan; 164(1):68-75. PubMed ID: 20854434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contaminated heparin associated with adverse clinical events and activation of the contact system.
    Kishimoto TK; Viswanathan K; Ganguly T; Elankumaran S; Smith S; Pelzer K; Lansing JC; Sriranganathan N; Zhao G; Galcheva-Gargova Z; Al-Hakim A; Bailey GS; Fraser B; Roy S; Rogers-Cotrone T; Buhse L; Whary M; Fox J; Nasr M; Dal Pan GJ; Shriver Z; Langer RS; Venkataraman G; Austen KF; Woodcock J; Sasisekharan R
    N Engl J Med; 2008 Jun; 358(23):2457-67. PubMed ID: 18434646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethylenediaminetetraacetic acid (EDTA) in heparin.
    Coyne E; Messmore HL; Walenga JM; Fareed J; Wehrmacher WH
    Thromb Res; 1998 Jun; 90(5):245-6. PubMed ID: 9694247
    [No Abstract]   [Full Text] [Related]  

  • 30. Development and validation of an ion-exchange chromatography method for heparin and its impurities in heparin products.
    Thiangthum S; Vander Heyden Y; Buchberger W; Viaene J; Prutthiwanasan B; Suntornsuk L
    J Sep Sci; 2014 Nov; 37(22):3195-204. PubMed ID: 25146711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of increasing the sulfation level of chondroitin sulfate on anticoagulant specific activity and activation of the kinin system.
    Hogwood J; Naggi A; Torri G; Page C; Rigsby P; Mulloy B; Gray E
    PLoS One; 2018; 13(3):e0193482. PubMed ID: 29494632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A nanosensor for ultrasensitive detection of oversulfated chondroitin sulfate contaminant in heparin.
    Kalita M; Balivada S; Swarup VP; Mencio C; Raman K; Desai UR; Troyer D; Kuberan B
    J Am Chem Soc; 2014 Jan; 136(2):554-7. PubMed ID: 24127748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparin quality control in the Brazilian market: implications in the cardiovascular surgery.
    Melo EI; Pereira MS; Cunha RS; Sá MP; Mourão PA
    Rev Bras Cir Cardiovasc; 2008; 23(2):169-74. PubMed ID: 18820778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers.
    Wielgos T; Havel K; Ivanova N; Weinberger R
    J Pharm Biomed Anal; 2009 Feb; 49(2):319-26. PubMed ID: 19155153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of heparin API by near infrared reflectance and Raman spectroscopy.
    Spencer JA; Kauffman JF; Reepmeyer JC; Gryniewicz CM; Ye W; Toler DY; Buhse LF; Westenberger BJ
    J Pharm Sci; 2009 Oct; 98(10):3540-7. PubMed ID: 19117047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin-focus on safety.
    Golembiewski J
    J Perianesth Nurs; 2008 Aug; 23(4):276-8. PubMed ID: 18657765
    [No Abstract]   [Full Text] [Related]  

  • 37. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.
    Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hypersensitivity reaction and Chinese heparin].
    Désormeaux A; Montpas N; Adam A
    Ann Pharm Fr; 2009 May; 67(3):169-72. PubMed ID: 19446665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The development of an FIA-CD strategy for screening sulfated polysaccharides using antimalarial drugs and related species as probes.
    Stanley FE; Warner AM; Stalcup AM
    Anal Bioanal Chem; 2011 Jan; 399(2):707-16. PubMed ID: 20941481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contaminants in heparin.
    Hull R; Walenga J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):125. PubMed ID: 21406418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.